Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 1:13:8989-8998.
doi: 10.2147/CMAR.S287908. eCollection 2021.

Current Insights into the Management of Late Chemotherapy Toxicities in Pediatric Osteosarcoma Patients

Stefanie Hecker-Nolting  1 , Thorsten Langer  2 , Claudia Blattmann  1 , Leo Kager  3 , Stefan S Bielack  1   4
Affiliations
Review

Current Insights into the Management of Late Chemotherapy Toxicities in Pediatric Osteosarcoma Patients

Stefanie Hecker-Nolting et al. Cancer Manag Res. .

Abstract

With ever increasing long-term, disease free survival rates, long-term toxicities of otherwise successful therapy have gained increasing importance. They can be grouped into potentially life-threatening, especially secondary malignancies and anthracycline cardiomyopathies, potentially disabling, particularly severe hearing loss and renal insufficiency, other, and rare events. Pathophysiology, frequency, and medical treatment approaches are discussed. Finally, fertility issues and quality of life issues are discussed, together with an outlook into the future. The challenge to cure as many patients as possible from osteosarcoma while enabling a life free of late effects will remain.

Keywords: adolescent; chemotherapy; child; late effects; osteosarcoma.

PubMed Disclaimer

Conflict of interest statement

Stefanie Hecker-Nolting report that her institution received financial support from EISAI. Thorsten Langer, and Claudia Blattmann report no conflicts of interest. Leo Kager reports financial compensation for advisory board roles for Bayer, Novartis, Amgen, and Agios, outside of the scope of this work. Stefan S Bielack reports financial compensation for advisory board roles for Bayer Healthcare, Boehringer Ingelheim, Hoffmann-La Roche, Ipsen, Eli Lilly, and Sensorion, all outside of the scope of this work. The authors report no other conflicts of interest in this work.

References

    1. Bielack S, Cable MG, Gorlick R, et al. Osteosarcoma - approach to therapy. C. A. S. Arndt (ed.), Sarcomas of bone and soft tissues in children and adolescents. Pediatr Oncol. 2021:91–109. doi: 10.1007/978-3-030-51160-9_8 - DOI
    1. Gaspar N, Marques da Costa ME, Fromigue Oet al. Recent Advances in Understanding Osteosarcoma and Emerging Therapies. Fac Rev. 2020;9:18. doi: 10.12703/r/9-18 - DOI - PMC - PubMed
    1. Just MA, Van Mater D, Wagner LM. Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma. Pediatr Blood Cancer. 2021;24:e29084. doi: 10.1002/pbc.29084 - DOI - PMC - PubMed
    1. Hawkins M, Bhatia S, Henderson TO, et al. Subsequent primary neoplasms: risks, risk factors, surveillance, and future research. Pediatr Clin North Am. 2020;67(6):1135–1154. doi: 10.1016/j.pcl.2020.07.006 - DOI - PubMed
    1. Möller TR, Garwicz S, Barlow L, et al. Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J Clin Oncol. 2001;19(13):3173–3181. doi: 10.1200/JCO.2001.19.13.3173 - DOI - PubMed